We are live on ! Find out more
IGMS

IGM Biosciences
IGMS

Delisted

IGMS was delisted on the 13th of August, 2025.

Back to rankings

72 hedge funds and large institutions have $183M invested in IGM Biosciences in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

594% more call options, than puts

Call options by funds: $222K | Put options by funds: $32K

0% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 21

0.99% less ownership

Funds ownership: 67.89% → 66.9% (-0.99%)

2% less capital invested

Capital invested by funds: $186M → $183M (-$3.46M)

9% less funds holding

Funds holding: 79 → 72 (-7)

29% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 24

Holders
72
Holders Change
-7
Holders Change %
-8.86%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
21
Reduced
21
Closed
24
Calls
$222K
Puts
$32K
Net Calls
+$190K
Net Calls Change
+$54K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$3.39M
2
AG
Artal Group
Luxembourg
+$3.36M
3
BBA
Baker Bros. Advisors
New York
+$3.1M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.32M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.12M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$5.14M
2
ECM
ExodusPoint Capital Management
New York
-$3.79M
3
Millennium Management
Millennium Management
New York
-$3.02M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.55M
5
OM
Opaleye Management
Massachusetts
-$2.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$30.7M +$3.1M +533,247 +17%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$27.1M +$100K +17,307 +0.5%
AG
3
Artal Group
Luxembourg
$25.8M +$3.36M +578,178 +23%
RG
4
Redmile Group
California
$24.7M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$14.1M -$2.55M -438,466 -21%
Goldman Sachs
6
Goldman Sachs
New York
$8.65M +$3.39M +583,516 +128%
RCM
7
RA Capital Management
Massachusetts
$7.79M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$7.46M -$16.6K -2,858 -0.3%
BlackRock
9
BlackRock
New York
$6.34M -$630K -108,446 -12%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$3.32M +$2.32M +400,000 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.71M +$198K +34,124 +12%
State Street
12
State Street
Massachusetts
$2.56M +$107K +18,371 +6%
Millennium Management
13
Millennium Management
New York
$2.05M -$3.02M -520,867 -68%
Citadel Advisors
14
Citadel Advisors
Florida
$1.76M +$1.12M +192,656 +1,022%
RPAM
15
Rhenman & Partners Asset Management
Sweden
$1.66M – – –
Morgan Stanley
16
Morgan Stanley
New York
$1.58M +$675K +116,288 +158%
SB
17
Samsara BioCapital
California
$1.29M – – –
Northern Trust
18
Northern Trust
Illinois
$1.14M +$5.88K +1,013 +0.7%
EAM
19
Exome Asset Management
New York
$1.13M +$787K +135,596 New
Hudson Bay Capital Management
20
Hudson Bay Capital Management
Connecticut
$1.03M – – –
Charles Schwab
21
Charles Schwab
California
$1M +$122K +21,052 +21%
TD Asset Management
22
TD Asset Management
Ontario, Canada
$693K – – –
WP
23
Woodline Partners
California
$623K – – –
Prudential Financial
24
Prudential Financial
New Jersey
$547K +$382K +65,870 New
BC
25
Bruce & Co
Illinois
$540K -$319K -55,000 -46%
1
2 3 4

IGMS Hedge Fund Activity: Q4 2023 in Review

72 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q4 2023, worth a combined $183M — down 1.9% from $186M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of IGMS and 17 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 21 added.

The largest buyer was Goldman Sachs, adding an estimated $3.39M. The largest seller was Great Point Partners, exiting entirely with an estimated $5.14M sold.

  • 72 institutional investors held IGM Biosciences (IGMS) as of Q4 2023, down from 79 in Q3 2023.
  • Funds reported $183M of IGM Biosciences stock for Q4 2023, down 1.9% quarter-over-quarter.
  • 17 funds opened new IGM Biosciences positions in Q4 2023 and 24 closed out, a net change of -7 holders.
  • The largest IGM Biosciences buyer in Q4 2023 was Goldman Sachs, an estimated $3.39M added.
  • The largest IGM Biosciences seller in Q4 2023 was Great Point Partners, an estimated $5.14M sold.

Based on aggregated 13F filings for Q4 2023.